ALERT: NEW ARTICLE
IDSA Clinical Infectious Diseases; Emergence and spread of Clostridioides difficile Isolates with Reduced Fidaxomicin Susceptibility in an Acute Care Hospital
Latest Financial Results
FY 2024
Fiscal Year Ended Dec 31, 2024
Stock Information
Company Overview
Acurx Pharmaceuticals is a publicly held clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. Acurx's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes early stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin- Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).
Investor Contact Information
Company
Acurx Pharmaceuticals, Inc.
259 Liberty Avenue
Staten Island, NY 10305
Investor Relations
In-Site Communications
Lisa Wilson